RegenCen: Dr. Gustav Lo, MD

RegenCen, led by Dr. Gustav Lo, MD, operates in Grand Rapids, Michigan, with a clinical focus on metabolic health optimization and hormone-related weight management. The practice integrates peptide-based therapies into individualized treatment protocols designed for patients seeking medically supervised approaches to metabolic dysfunction, weight regulation, and body composition improvement. Dr. Lo's practice serves patients throughout Michigan and Florida through both in-person consultations in Grand Rapids and telehealth appointments, providing access to prescription peptide therapies for eligible candidates in these states.

The primary therapeutic intervention offered at RegenCen is semaglutide, a GLP-1 receptor agonist peptide originally developed for type 2 diabetes management and now widely utilized in medical weight loss protocols. Semaglutide functions by mimicking the incretin hormone GLP-1, which regulates appetite, slows gastric emptying, and improves insulin sensitivity. Dr. Lo prescribes semaglutide as part of comprehensive metabolic health programs that address underlying factors contributing to weight gain, insulin resistance, and metabolic syndrome. The clinic's protocols typically involve weekly subcutaneous injections with dosing titrated based on individual patient response, tolerance, and metabolic markers tracked through regular laboratory monitoring. Patients receiving semaglutide therapy at RegenCen undergo baseline metabolic assessments including fasting glucose, hemoglobin A1C, lipid panels, and thyroid function tests to establish treatment appropriateness and monitor progress.

Dr. Gustav Lo brings his medical degree and clinical training to a practice model that emphasizes root-cause analysis of metabolic dysfunction rather than symptom management alone. His approach to semaglutide therapy incorporates nutritional counseling, lifestyle modification strategies, and ongoing metabolic monitoring to optimize patient outcomes beyond weight reduction. Dr. Lo evaluates patients for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disorders before initiating peptide therapy. The practice maintains protocols for managing common side effects such as nausea, constipation, and injection site reactions, with dosing adjustments made based on individual tolerance patterns.

Patients beginning treatment at RegenCen can expect an initial consultation that includes comprehensive medical history review, discussion of weight loss goals and previous attempts, metabolic health assessment, and education about semaglutide's mechanism of action and expected timeline for results. The hybrid consultation model allows Grand Rapids-area patients to choose in-person visits at the Michigan clinic or virtual appointments, while Florida residents access care exclusively through telehealth. Follow-up appointments typically occur monthly during the initial titration phase, then transition to quarterly visits once therapeutic dosing is established. The practice provides patients with detailed injection technique training, supplies including syringes and alcohol swabs, and clear protocols for medication storage and handling. Dr. Lo's treatment plans generally span six to twelve months, with ongoing assessment of whether continued therapy remains medically appropriate based on weight loss progress, metabolic marker improvements, and patient tolerance.

RegenCen differentiates itself through its focused scope of practice, allowing Dr. Lo to develop deep expertise in GLP-1 peptide therapy applications rather than offering a broad menu of treatments. The clinic's telehealth infrastructure enables patients in both Michigan and Florida to access specialized metabolic health care without geographic barriers, with medications shipped directly to patient homes through partner pharmacies. This streamlined approach appeals to patients seeking medical weight loss support from a physician who understands the complex interplay between hormones, metabolism, and body composition, particularly those who have not achieved sustainable results through diet and exercise alone or who present with metabolic conditions that benefit from pharmaceutical intervention.